| Literature DB >> 30724344 |
Snehal Surana1, Ratna Kumar2, Matthew Pitt3, Patricia Hafner3,4, Ailsa Mclellan5, Joyce Davidson6, Prab Prabakhar1, Angela Vincent5, Yael Hacohen1,7, Sukhvir Wright2,8.
Abstract
Acquired neuromyotonia is a form of peripheral nerve hyperexcitability. In adults, pathogenic antibodies that target the extracellular domains of leucine-rich glioma-inactivated protein 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) have been reported. We describe three paediatric patients with acquired neuromyotonia and CASPR2 and LGI1 serum antibodies. They all presented with acute-onset myokymia and pain in the lower limbs; one patient also had muscle weakness. Electromyography was suggestive of peripheral nerve hyperexcitability. Two patients improved without immunotherapy; one treated patient remained immunotherapy-dependent. Although not fatal, acquired paediatric neuromyotonia can be disabling. It is amenable to symptomatic treatment or may undergo spontaneous recovery. More severe cases may require rational immunotherapy. WHAT THIS PAPER ADDS: The symptoms of neuromyotonia may resolve spontaneously or may require sodium channel blockers. Patients with debilitating symptoms who are refractory to symptomatic therapy may require immunotherapy.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30724344 DOI: 10.1111/dmcn.14179
Source DB: PubMed Journal: Dev Med Child Neurol ISSN: 0012-1622 Impact factor: 5.449